Arvinas, Inc.
NASDAQ:ARVNBiotechnology
-$0.10 today
- Market cap
- $443.01M
- Beta
- 1.75
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$3.46
Volume 1.09M
Average 0.89M
ARVN Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Arvinas, Inc.NASDAQ: ARVN
Gross Margin · Q1 FY2026 · quarter ended Mar 2026
Gross margin narrows to 92.9%
Gross margin was 92.9% in Q1 FY2026, down 7.1 pp from a year earlier. On a trailing-twelve-month basis it was 97.4%, down 2.2 pp year over year. Over 3 fiscal years it narrowed by 2.0 pp.
Context
- Gross margin widened in 0 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 98.0%
- Year-over-year change
- -2.0pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 98.0% | -2.0pp |
| FY2024 | 2024-12-31 | 100.0% | +0.0pp |
| FY2023 | 2023-12-31 | 100.0% | +0.0pp |
| FY2022 | 2022-12-31 | 100.0% | +0.0pp |
| FY2021 | 2021-12-31 | 100.0% | — |
Gross Margin vs competitors
How ARVN compares with its peers on the latest reported figures
- ARVN's LTM Mar 2026 gross margin of 97.4% is the 2nd highest of the 6 companies compared; the peer median is 94.8%.
- Its year-over-year change of -2.2 pp is the 4th highest of 6, against a peer median of +6.6 pp.
- Over three fiscal years its change of -2.0 pp compares with a peer median of -5.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 102.0% | +6.6 pp | +0.0 pp | |
| LTM Mar 2026 | 97.4% | -2.2 pp | -2.0 pp | |
| LTM Mar 2026 | 95.3% | -3.4 pp | — | |
| LTM Mar 2026 | 94.8% | +9.6 pp | -22.2 pp | |
| LTM Aug 2026 | 86.5% | +249.4 pp | +455.2 pp | |
| LTM Mar 2026 | 22.3% | -77.7 pp | -10.8 pp | |
| Peer median (excluding ARVN) | 94.8% | +6.6 pp | -5.4 pp | |
Competitors are the stored peer set for ARVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 53.6M | 131.4M | 78.5M | 263.4M | 262.6M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 5.2M |
| Gross Profit | 53.6M | 131.4M | 78.5M | 263.4M | 257.4M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 98.0% |
| Research & Development | 180.4M | 315M | 379.7M | 348.2M | 282.9M |
| Selling, General & Admin | 61.6M | 79.6M | 100.3M | 165.4M | 89.4M |
| Operating Expenses | 242M | 394.6M | 480M | 513.6M | 372.3M |
| Depreciation & Amortization | 6M | 8.2M | 6.7M | 6.6M | 5.2M |
| EBITDA | (184.9M) | (253.4M) | (359.7M) | (191.7M) | (75.3M) |
| EBITDA Margin | -345.0% | -192.8% | -458.2% | -72.8% | -28.7% |
| Operating Income | (188.4M) | (263.2M) | (401.5M) | (250.2M) | (114.9M) |
| Operating Margin | -351.5% | -200.3% | -511.5% | -95.0% | -43.8% |
| Interest Income | 1.8M | 12M | 38.8M | 54.8M | 22M |
| Interest Expense | 100K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (2.6M) | 1.6M | 35.1M | 51.9M | 34.4M |
| Income Before Tax | (191M) | (261.6M) | (366.4M) | (198.3M) | (80.5M) |
| Pre-Tax Margin | -356.3% | -199.1% | -466.8% | -75.3% | -30.7% |
| Income Tax Expense | 0 | 20.9M | 900K | 600K | 300K |
| Net Income | (191M) | (282.5M) | (367.3M) | (198.9M) | (80.8M) |
| Net Margin | -356.3% | -215.0% | -467.9% | -75.5% | -30.8% |
| EPS (Basic) | (3.82) | (5.31) | (6.62) | (2.77) | (1.28) |
| EPS (Diluted) | (3.82) | (5.31) | (6.62) | (2.77) | (1.28) |
| Weighted Avg Shares | 50M | 53.2M | 55.5M | 71.9M | 64.9M |
| Weighted Avg Shares (Diluted) | 50M | 53.2M | 55.5M | 71.9M | 64.9M |
Arvinas, Inc.
NASDAQ:ARVN
Intrinsic Alpha fair value
Locked
Current Price
$6.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.